Mounjaro 5.0 mg: what this dose actually does

The moment the pen arrives and you're looking at a new strength

Picture this: a small DPD parcel turns up the next working day, plain on the outside, and inside is a KwikPen labelled 5 mg. You've been on 2.5 mg for four weeks. The starter pen did its job, it let your system adjust to tirzepatide without the full force of a therapeutic dose hitting at once. Now the work shifts.

At 5.0 mg, tirzepatide activates both the GIP and GLP-1 receptors with more intensity. Gastric emptying slows a little further; signals of fullness reach the brain more firmly. For many people, this is the pen where the appetite reduction they'd read about becomes something they actually feel, smaller portions, less grazing between meals, a reduced pull toward food in the evenings.

That said, the body is still adjusting. Nausea, loose stools or indigestion can resurface briefly after moving up from 2.5 mg, in the same pattern they might have appeared at the very start. Most people find these settle within one to two weeks. If they don't, or if they're severe, that's a conversation for your prescriber, not something to push through silently. You can read a fuller breakdown of what to expect on our side effects at Mounjaro 5.0 mg page.

The NHS medicines page for tirzepatide covers the full side-effect profile clearly, including which symptoms to treat as urgent.

What the clinical evidence shows at this strength

The SURMOUNT-1 trial (the pivotal study behind Mounjaro's UK licence) ran participants through the full escalation schedule from 2.5 mg up to either 10 mg or 15 mg. Nobody stayed at 5 mg as a maintenance dose in the trial, because the protocol was designed to titrate further. What that means in practice: the dramatic headline figures (around 20–21% average body-weight reduction at 15 mg over 72 weeks) are achieved at higher doses, not at 5 mg alone.

What 5 mg does is establish the pattern. Appetite changes are real at this strength, and early weight movement often appears in weeks four to eight for people who respond well. But 5.0 mg is a step, not a destination, the full Mounjaro dose range continues through 7.5, 10, 12.5 and 15 mg, and the prescriber's job is to find the dose where your results are good and your tolerance is comfortable.

If you're comparing Mounjaro's overall clinical performance against other licensed options, our treatment overview sets out what the evidence shows across the medicines we prescribe.

Who might stay at 5 mg longer, and who moves up sooner

Titration timing is a clinical call, not a rule of thumb. Some people stay at 5.0 mg for longer than four weeks because side effects are still present, or because their prescriber judges that the body needs more time to settle. If you want to understand exactly what this strength involves before committing to it, our Mounjaro 5 mg page walks through the detail in full. Others move up on schedule because they're tolerating it well and the appetite effect is modest.

There is no fixed rule that says 5 mg is inadequate, NICE's guidance on tirzepatide (TA1026) frames the aim as reaching the highest tolerated dose, not a specific number. That framing matters: a person who loses meaningful weight at 5 mg with good tolerance may not need to go higher, at least for a period.

Private eligibility for Mounjaro broadly requires a BMI of 30 or above, or 27 or above alongside a weight-related condition such as hypertension or high cholesterol. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. BMI alone never settles the question, the full picture is what the prescriber weighs up. If you're thinking about what happens once you've reached your goal weight, the Mounjaro maintenance dose page covers that territory.

Wondering about the cost side? The Eli Lilly price increase page gives honest context on how UK pricing has shifted since September 2025 and what to factor into your planning.

How to get 5.0 mg through a legitimate route

Mounjaro 5.0 mg is a prescription-only medicine. The only legal route in the UK is a prescription issued following a clinical assessment by a registered prescriber. Buying any strength of tirzepatide without that process (from a social-media seller, an unverified website, or anyone offering it without clinical oversight) is both a legal and a safety risk. The MHRA has seized large quantities of fake weight-loss pens in recent years; counterfeit pens have been found to contain the wrong substances entirely.

At nume, every consultation is read by a GPhC-registered Independent Prescriber on the same day it's submitted. If you are earlier in the titration schedule and currently weighing up whether 4 mg Mounjaro is the right starting point for your plan, that page sets out who it suits and how it fits into the broader escalation pathway. If 5 mg is appropriate for where you are in your treatment, they'll confirm it and your prescription is processed the same working day. You can verify our pharmacy on the GPhC register at registration number 9012878.

To find out whether you're a candidate for Mounjaro and where 5.0 mg fits in your specific plan, check your eligibility with our prescribers, the consultation is free, and there's no obligation.